### Presentation on:

# **JL** ABL **T** Medical<sup>™</sup>







# JL ABL Medical<sup>™</sup>

- Our father, Bill Moeller, was devoted to making the world a better place with a core value of living healthy.
- He was aware of the health benefits of silver, but was not satisfied with the available products and their safety.
- He worked with a chemist and an electrical engineer to improve on existing silver technology, but instead, they discovered a completely new technology. From this SilverSol<sup>®</sup>, was developed.
- He founded the American Biotech Labs in 1998 with his five sons. Within years, his grandchildren also joined this growing company as the third generation.
- The medical division of American Biotech Labs is called ABL Medical.
- Thousands of lives have been saved to date, while tens of thousands more have been helped.
- American Biotech Labs (ABL) maintains its dedication to research with over 400 independent studies.
- In 2013, SilverSol<sup>®</sup> was studied in the first human clinical trials done on a nano-silver particle, showing that SilverSol<sup>®</sup> is completely safe.

### Our **beliefs**.

We believe that strengthening one's physical well being will further the ability to live a more balanced life, including mentally and spiritually, and essentially empower an active lifestyle with confidence.

By combining the awesomeness of nature and the power of science, American Biotech Labs continues to research and develop innovative products that help consumers live a stronger and healthier lifestyle by safeguarding their health.



# Our Mission.



To help our customers and consumers live an active and balanced lifestyle through the empowerment of a strong, healthy physical self.

# ABL Medical SILVER Technology.


- **Global Leader In Nano-Silver Technology**
- Patented 56 Patents Globally Patents Pending
- **Pharmacy Grade For Prescription & OTC**
- Does Not Affect The Taste Or Smell Of The Products It Is Used In
- Used as a Preservative In Hundreds of Products Stable - Can Be Frozen Or Boiled Without Change
- More Than 22,000,000 Units Sold Worldwide
- No Reported Side Effects Or Negative Interactions

- Calorie Free
- Stable and Versatile
- Contains:
  - ✓ No Parabens
  - ✓ No Alcohol
  - ✓ No Sorbates
  - ✓ No Benzoates
  - ✓ No Quaternary Ammonium

Medical

Compounds






Millions of dollars invested in safety and efficacy tests, with continued expansion of approved uses and patents.

SilverSol Technology<sup>®</sup> shown safe with more than 30 safety studies and the only double-blind, IRB-Board Certified, FDA-Cleared, human-ingestion safety clinical.

We have FDA-cleared Rx and OTC products that use SilverSol Technology, and many more products pending.







# WOUND CARE silver gel.

• Our antibacterial silver wound dressing gel is indicated for the OTC local management of:



- And by the order of a licensed healthcare practitioner for the management of:
  - ✓ Wounds Such as Stasis Ulcers, Pressure Ulcers, and Diabetic Ulcers
  - Device Insertion Site Wounds
  - ✓ Surgical Incision Sites
  - ✓ Graft Sites
  - ✓ Donor Sites
  - ✓ Skin Tears





# Silver Wound Gel purpose/ingredients.

- Our antibacterial silver wound dressing gel contains silver that in laboratory tests has been shown to inhibit the growth of microorganisms such as:
  - Staphylococcus Aureus
     Pseudomonas Aeruginosa
     Escherichia Coli
     Antibiotic Resistant Strains
     MRSA
     VRE
     Fungi Such As Candida Albicans
- Made with Patented Silver Technology
  - No Stinging
     No Staining
     No Sticking
     No Chloride
     No Scent
- Probiotic friendly
- **Contents:** 32 ppm Proprietary Silver (purified water, nano-silver at .01 micron), Propylene Glycol, Triethanolamine, Carbomer.





# <u>Silver Wound Gel</u> Purpose/ingredients.

- Our antibacterial silver wound dressing gel contains:
  - ✓ No Sulfa Components
  - ✓ No Alcohol
  - Non-Toxic
  - ✓ Chloride Free
  - ✓ Non-Flammable
- SilvrSTAT hydrates and acts as prevention-based product; contains no alcohol or petroleum, so it won't dry out the skin or leave a greasy feeling. It pulls into the top layer of the skin (or covers the wound) and forms a smooth protective barrier after application





PRODUCT	EXPOSURE INTERVAL	MRSA 3.8X10⁵ CFU/ml	VRE 7.2x10 <sup>5</sup> CFU/ml	oducts In Sa P. aeruginosa 5.2x10⁵CFU/ml	E. Coli 8.1x10⁵CFU/ml	C. albicans 6.8x10⁵CFU/ml	S. agalac 4.3x10 <sup>s</sup> CF
	10 min	220000	500000	<10	8000	<10	25000
	1 hr	1200	10000	<10	<10	<10	15000
SilvrSTAT®	4 hr	200	250	<10	<10	<10	<10
	24 hr	<10	<10	<10	<10	<10	<10
	10 min	18000	450000	300	500000	700	8500
Medical	1 hr	10000	180000	100	350000	<10	8000
Grade Honey	4 hr	20000	150000	<10	200000	<10	800
	24 hr	<100	600	<10	1300	<10	100
	10 min	<10	400000	65000	500000	150000	<10
Mupirocin	1 hr	<10	150000	700	80000	40000	<10
Ointment	4 hr	<10	150000	<10	16000	14000	<10
	24 hr	<10	180000	100	<10	12000	<10
	10 min	150000	350000	180000	450000	250000	28000
Ionic Silver	1 hr	80000	35000	<10	75000	40000	3500
Gel	4 hr	200	15000	<10	<10	35000	200
	24 hr	200	18000	<10	<10	800	<10
Silver	10 min	120000	350000	1300	65000	7000	4000
Sulfadiazine	1 hr	2000	7000	100	300	100	100
	4 hr	300	<10	100	100	<10	<10
Cream	24 hr	100	100	<10	<10	100	<10
Botanical Extract Gel	10 min	150000	420000	500	5500	14000	8000
	1 hr	75000	200000	100	200	300	3000
	4 hr	15000	200000	<10	<10	<10	100
	24 hr	<10	40000	<10	<10	100	200

# Independent *In Vitro* Report on Antimicrobial Effects of the Active Ingredient in SilvrSTAT<sup>®</sup>

Kill Time Study with 32PPM Gel						
Organism	Exposure Interval	Avg. Control Titer (CFU/ml)	Percent Reduction	Log Reduction		
MRSA	1 HR	1.9 x 10 <sup>6</sup>	>99.99	>4.98		
INIKJA	24 HR	1.9 x 10 <sup>6</sup>	>99.99	>4.98		
P. Aeruginosa	1 HR	2.1 x 10 <sup>6</sup>	>99.99905	>5.02		
	24 HR	2.1 x 10 <sup>6</sup>	>99.99905	>5.02		
VRE	1 HR	1.9 x 10 <sup>6</sup>	>99.56	2.35		
VKE	24 HR	1.9 x 10 <sup>6</sup>	>99.99	>5.38		

	Not less than 1.0 log reduction from the initial calculated count at 7 days, not less than 3.0 log reduction from the initial count at 14 days, and no increase from the 14 days count at 28 days
--	---

FDA Required Time Study: Nelson Laboratories (#474527, #474527A, #474527B, #474527C, #474527D, #474527E Data on File



### Independent *In Vitro* Report on the Antibacterial Effects of the Active Ingredient in SilvrSTAT<sup>®</sup>

Disinfectant Efficacy Results @ 5 and 10 Minutes of 60 Different Tests Per Bacteria

ORGANISM	TIME POINT (MIN.)	CARRIER TITER (CFU/CARRIER)	NUMBER OF CARRIERS TESTED	NUMBER SHOWING GROWTH	NUMBER SHOWING NO GROWTH
P. aeruginosa	5	5.5 x 10 <sup>4</sup>	60	0	60
	10	5.5 x 10 <sup>4</sup>	60	1	59
S. aureus	5	5.5 x 10 <sup>6</sup>	60	6	54
Summers 1	10	5.5 x 10 <sup>6</sup>	60	1	59
S. choleraesuis	5	5.5 x 10 <sup>6</sup>	60	1	59
	10	5.5 x 10 <sup>6</sup>	60	0	60

Data on File



# addendum.

M. S. will

632

THE LOW LOW TO STORE

Sugar Al.

the logitude

Medical

and the second states of

# Benefits of **ABL Silver Technology.**

- Provides a clear protection barrier, that lasts up to three (3 days, and has a cytotoxicity rating of 1, just as 'safe as water'
- In comparing our wound care silver gel with other products in same regulatory category (including triple antibiotic ointment) using comparison date measuring kill rate and duration of kill, our wound care silver gel virtually eliminated pathogens within 24 hours via Independent In Vitro studies
- 420+ reports and studies
- 5 human ingestion studies When ingested, no negative action with other drugs, on blood platelets, organs, and body systems
- Probiotic studies showing that our patented nano-silver, does no damage to probiotic systems
- No Silver buildup; no accumulation. Particles exit the body within 24 hours, unlike other forms of silver
- No known or expected adverse events due to the low 24ppm silver concentration



# <u>ABL Medical's SILVER IS SAFE.</u>

- Over 400 Independent Studies & Test Reports Performed By More Than 60 Leading Independent Laboratories, Universities, Government, & Military Labs
- 3 Published & FDA Cleared Human Ingestion Studies
- Peer-Reviewed & Published Scientific & Medical Journal Articles

- Available upon request:
  - ✓ Safety Studies
  - ✓ USP 51 Challenge Tests
  - ✓ Key Publications
  - ✓ Clinical Trials
  - ✓ Product Demonstration Videos



### Independent In Vitro Report on SilvrSTAT®

Organism at control titer of 1,000,000 to 10,000,000 CFU/ml	0 hour Log <sub>10</sub> reduction results	7 day Log <sub>10</sub> reduction results	14 day Log <sub>10</sub> reduction results	28 day Log10 reduction results
Staphylococcus aureus	0.91	>4.72	>4.72	>4.72
Pseudomonas aeruginosa	>3.31	>4.31	>4.31	>4.31
Escherichia coli	>3.12	>4.56	>4.56	>4.56
Candida albicans	>3.73	>4.73	>4.73	>4.73

Organism	Exposure interval	Average control titer (CFU/ml)	Percent reduction (%)	Log <sub>10</sub> reduction
Methicillin-resistant <i>Staphylococcus</i> aureus (MRSA), ATCC#4330	1 hour	1,900,000	99.9989	>4.98
Methicillin-resistant <i>Staphylococcus</i> <i>aureus</i> (MRSA), ATCC#4330	24 hours	1,900,000	99.9989	>4.98
Vancomycin-resistant Enterococcus faecalis (VRE), ATCC#51575	1 hour	4,800,000	99.56	2.35
Vancomycin-resistant Enterococcus faecalis (VRE), ATCC#51575	24 hour	4,800,000	>99.99958	>5.38

Data on File



### **SILVESTAT**<sup>®</sup> THE NEXT GENERATION IN WOUND DRESSINGS



**Day 1** 4.2 x 3.4 x 0.2 cm

### **Patient Summary**

33-year-old patient was seen in the hospital for an infected right great toe ulceration. Patient has had previous history of diabetic foot infections and this was his 3rd occurrence on this foot. Patient had extreme pain to his right foot on clinical presentation. 2.0 diameter ulcer to medial aspect of right great toe. 4 cm tunnel from proximal plantar 1st MPJ to distal plantar right great toe. No probing to bone identified.

**PMH:** IDDM (x 26 years); depression; asthma; left great toe amputation (2012) **Allergies:** Erythromycin and iodine

### **Clinical Course**

Operative treatment included debridement and incision/drainage of abcess. Application of SilvrSTAT<sup>®</sup> changed every 3 days.



### THE NEXT GENERATION IN WOUND DRESSINGS



**Day 8** 3.5 x 2.5 x 0.15 cm



**Day 18** 1.5 x 2.0 x 0.15 cm




EL-6



Data on File





- SilvrSTAT Antibacterial Wound Dressing Gel is indicated for the management of 1st and 2nd degree burns, wounds such as stasis ulcers, pressure ulcers, diabetic ulcers, lacerations, abrasions, skin tears, surgical incision sites, device insertion site wounds, graft sites and donor sites.<sup>2</sup>
- It is <u>not</u> an ionic silver.<sup>1</sup>
- SilvrSTAT should be applied directly to the affected area and covered with an appropriate dressing.<sup>2</sup>
- For burns, SilvrSTAT should be applied to the affected area and allowed to dry.
- There are no known adverse events associated with the use of SilvrSTAT for external wound management.<sup>2</sup>

### SilvrSTAT offers:

- Superior wound management
- Inhibition of broad spectrum bacteria including MRSA and VRE
- Visualization of the wound through a transparent gel
- No Sulfa or Alginate components
- No Alcohol


References

Non-flammable

### ABL Medical 801.763.8000 American Fork, UT 84003

www.ablmedical.com

1. R. Roy et al, Materials Research Innovations 2007 Vol 11 No 1 2. SilvrSTAT Antibacterial Wound Dressing Gel United States Package Insert ABL Medical Data On File



# Click here to try the **New PubMed!**

An updated version of PubMed is now available. Come see the new improvements to the interface!

Format: Abstract -

Send to -

JL ABL

Medical

J Wound Care. 2017 Apr 1;26(sup4):S16-S24. doi: 10.12968/jowc.2017.26.Sup4.S16.

### The ability of a colloidal silver gel wound dressing to kill bacteria in vitro and in vivo.

Tran PL<sup>1</sup>, Huynh E<sup>1</sup>, Hamood AN<sup>2</sup>, de Souza A<sup>3</sup>, Mehta D<sup>3</sup>, Moeller KW<sup>4</sup>, Moeller CD<sup>4</sup>, Morgan M<sup>5</sup>, Reid TW<sup>6</sup>.

Author information

### Abstract

**OBJECTIVE:** Inhibiting bacterial biofilms is of major significance for proper wound healing. The choice of the dressing material plays a key role, as bacteria can live in dressings and keep reinfecting the wound. This study examines the effectiveness of a colloidal silver gel (Ag-gel) wound dressing in inhibiting the growth of bacteria in a mouse wound model.

**METHOD:** Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and two different meticillin-resistant Staphylococcus aureus (MRSA) strains were examined. Bacteria were measured in vitro on the dressing, and in vivo studies were carried out to analyses both the dressing and the infected tissue. The silver gel product used was SilvrSTAT from ABL Medical, LLC.

**RESULTS:** Using colony-forming unit (CFU) assays, over 7 logs of inhibition (100%) were found for Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii for the Ag-gel dressing when compared with the control dressing. In vivo, complete inhibition was observered for the three most common bacteria on the Ag-gel dressing and the tissue under that dressing. These results were confirmed by an in vivo live imaging system. However, with MRSA strains, only 2-3 logs of inhibition were recorded.

CONCLUSION: The Ag-gel was effective in preventing biofilm infections caused by both Gram-negative and Gram-positive bacteria.

KEYWORDS: biofilm; in vitro model; in vivo model; infection; silver; wound; wound dressing

### Skin and Wound Care Quick Reference/Guideline Protocols Provided By MEDEON

### SILVRSTAT



Suspected Deep Tissue Injury (sDTI)



Stage I Pressure Ulcer



Stage II Pressure Ulcer Partial Thickness Skin Loss or Blister



2 300

Stage III Pressure Ulcer or Stage IV Pressure Ulcer or Full Thickness Wound

Purple or maroon localized area of discolored intact skin or blood-filled blister due to damage of underlying soft tissue from pressure and/or shear. Further description: The area may be preceded by tissue that is painful, firm, mushy, boggy, warmer or cooler as compared to adjacent tissue. Deep tissue injury may be difficult to detect in individuals with dark skin tones. Evolution may include a thin blister over a dark wound bed. The wound may further evolve and become covered by thin eschar. Evo- lution may be rapid exposing addi- tional layers of tissue even with treat- ment.	Intact skin with non-blanchable ery- thema of a localized area usually over a bony prominence. Discoloration of the skin, warmth, edema, hardness or pain may also be present. Darkly pigmented skin may not have visible blanching. <b>Further description:</b> The area may be painful, firm, soft, warmer or cooler as compared to adjacent tissue. Category/Stage I may be dif- ficult to detect in individuals with dark skin tones. May indicate "at risk" persons.	Partial thickness loss of dermis pre- senting as a shallow open ulcer with a red pink wound bed, without slough. May also present as an intact or open/ruptured serum filled or se- rosanginous filled blister. <b>Further description:</b> Presents as a shiny or dry shallow ulcer without slough or bruising. This catego- ry/stage should not be used to de- scribe skin tears, tape burns, inconti- nence associated dermatitis, macera- tion or excoriation.	<ul> <li>Stage III: Full Thickness tissue loss (fat visible) Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle is not ex- posed. Some slough may be present. May include undermining and tun- neling.</li> <li>Further description: The depth of a Category/Stage III pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) sub- cutaneous tissue and Category/Stage III ulcers can be shallow. In contrast, areas of significant adiposity can de- velop extremely deep Category/Stage III pressure ulcers. Bone/tendon is not visible or directly palpable.</li> </ul>	Stage IV: Full Thickness tissue loss (muscle/bone visible). Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present. Often include undermining and tunneling. Further description: The depth of a Category/Stage IV pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) sub- cutaneous tissue and these ulcers can be shallow. Category/Stage IV ulcers can extend into muscle and/or sup- porting structures (e.g. fascia, tendon or joint capsule) making osteomyeli- tis or osteitis likely to occur. Exposed bone/muscle is visible or directly pal- pable.
Prevention Guidelines •Pressure redistribution support sur- face as appropriate •Turn and reposition q 2h in bed and q 1h in chair •Offloading device to keep heels ele- vated off bed •Meeting here a last a the	Intact Skin Cleanse •Cleansing shampoo or foam Apply •Protective Barrier or Hydrocolloid	Dry to Scant Exudate Cleanse •Normal Saline Apply •Skin prep to periwound skin •SilvrSTAT Hydrogel Cover •Waterproof bordered gauze	Dry to Scant Exudate Cleanse •Normal Saline Apply •Skin prep to periwound skin •SilvrSTAT Hydrogel Cover •Waterproof bordered gauze	Dry to Scant Exudate Cleanse •Normal Saline Apply •Skin prep to periwound skin •SilvrSTAT Hydrogel Cover •Waterproof bordered gauze
•Monitor skin at least q 8hrs Cleanse •Cleansing Shampoo, Foam, or Body Wash		Change •Daily or as indicated by type and condition of the wound	Change •Daily or as indicated by type and condition of the wound	Change •Daily or as indicated by type and condition of the wound
Apply •Skin Repair Cream to moisturize skin		Moderate to Heavy Exudate Cleanse •Normal Saline	Moderate to Heavy Exudate Cleanse •Normal Saline	Moderate to Heavy Exudate Cleanse •Normal Saline
•Skin prep for at risk skin •Zinc prep for compromised skin •SilvrSTAT for yeast/fungus		Apply •Skin prep to periwound skin •SilvrSTAT hydrogel to base •Alginate filler	Apply •Skin prep to periwound skin •SilvrSTAT hydrogel to base •Alginate filler	Apply •Skin prep to periwound skin •SilvrSTAT hydrogel to base •Alginate filler
		Cover •Silicone adhesive foam gentle/Super absorbent dressing	Cover •Silicone adhesive foam gentle/Super absorbent dressing	Cover •Silicone adhesive foam gentle/Su- per absorbent dressing
L ABL Medical <sup>™</sup>		Change •Daily or as indicated by type and condition of the wound	Change •Daily or as indicated by type and condition of the wound	Change •Daily or as indicated by type and condition of the wound
				Rev 10/14

### Skin and Wound Care Quick Reference/Guideline Protocols Provided By MEDEON

### SILVRSTAT





Unstageable Pressure Ulcers

logical) cover" and should not be removed.

Solid Dry Eschar on Heels

Float heels to relieve pressure

Cover

No Dressing


**JL** ABL **T** Medical<sup>™</sup>

·Keep Dry

Necrotic Wounds







### Independent In Vitro Report on the Cytotoxicity of SilvrSTAT®


The MEM Elution test was designed to determine the cytotoxicity of extractable substances. An extract of the sample was added to cell monolayers and incubated. The cell monolayers were examined and scored based on the degree of cellular destruction. The cell monolayers were examined microscopically. The wells were scored as to the degree of discernable morphological cytotoxicity on a relative scale of 0 to 4:


CONDITIONS OF ALL CULTURES	REACTIVITY	GRADE
No cell lysis, intracytoplasmic granules.	NONE	0
Not more than 20% rounding, occasional lysed cells.	SLIGHT	1
Not more than 50% rounding, no extensive cell lysis.	MILD	2
Not more than 70% rounding and lysed cells.	MODERATE	3
Nearly complete cell destruction.	SEVERE	4


DENTIFICATION	SCORE #1	SCORE #2	SCORE #3	AVERAGE	
Negative Control	0	0	0	0	
Media Control	0	0	0	0	
Positive Control	4	4	4	4	
429606 Lot #060908	1	1	1	1	



### Independent In Vitro Report of SilvrSTAT® vs Silver Sulfadiazine







- SilvrSTAT<sup>®</sup> 32ppm vs. Silver Sulfadiazine (SSD) 10,000ppm to determine the killing curve of both products *in vitro*.
- Despite the lower concentration of silver, SilvrSTAT<sup>®</sup> provides quicker bactericidal activity versus the commonly used silver sulfadiazine.
- Wounds free of pathogens may heal more quickly than those which have high bacterial loads.



### Healing a Complicated Wound Using a Multivalent Silver Nanoparticle Gel

Adam Falivene, BA; Anthony R. Iorio, DPM, MPH, FACWCA New York College of Podiatric Medicine

### INTRODUCTION

Silver has been used for centuries in medicine and in hygiene, largely due to bactericidal and broad-spectrum antimicrobial activity. By the seventeen hundreds silver nitrate was being used for treatment of ulcers. Silver is regularly used now in wound care and medical devices for dental work and catheters. Silver Sulfadiazine, a topical treatment, has regularly been used to treat burn wounds. At this stage, nanotechnology is being used create silver nanoparticles which are more efficient than silver ions alone.

Nanoparticles are particles smaller than 100 nm and the effectiveness of silver nanoparticles has been widely tested and shown to have broad spectrum antibacterial properties for Gram-positive and Gram-negative bacteria. Silver Nanoparticles are known to have strong bacteriocidal effects on many bacteria. different types of includina Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, ampicillin resistant E. Coli and S. Pyogenes. Their biological activity stems from its associated silver ion and its soluble complexes that generate reactive oxygen species. Specifically, the silver ion binds to thiol groups in key enzymes causing a disruption of the bacterial respiratory chain. The reactive oxygen species created in this process cause oxidative stress and cell damage to the bacteria. Interestingly, the small form of nanosilver particles, offers a large surface area to volume ration in its application, increasing the potential for silver ions to be released in the affected area.

SilvrSTAT® is a multivalent silver nanoparticle gel that was released as a antibacterial wound dressing gel in 2012. It's active ingredient is a nanoparticle that has a core of metallic silver with a coat of tetra silver tetroxide (Ag4O4) that has areas of positive charge and negative charge. This molecule is partly ionic and partly covalent, with two silver atoms in the +1 oxidation state and two silver atoms in the +3 oxidation state, making it multivalent and a very powerful oxidizing agent. When one of the areas of positive charge comes within close contact to a bacterial cell wall, it dislodges electrons and causes immediate collapse of the cell wall. The advantage of this multivalent silver nanoparticle is that it is able to kill bacteria rapidly and stay effective at relatively low levels of silver concentration; 32ppm, Our hypothesis is that by using this multivalent silver nanoparticle gel on a diabetic ulcer, we will see faster and improved ulcer closure than with another hydrogel.

### CASE STUDY

A 66-year-old female with a history of uncontrolled Type II Diabetes Mellitus and diabetic peripheral neuropathy presents with two ulcers – one on the plantar aspect of each foot .The patient was diagnosed with Multiple Sclerosis five years ago. She has NKDA and denies a history of smoking, but drinks 1 to 2 drinks daily. Pre-treatment the wound on the left measured 1 cm x 1 cm x 0.1 cm, with granular, erythematous base and hyperkerototic border. The patient followed up with us for weekly standard of care treatment by mechanical debridement, infection control, and appropriate offloading and dressing of both the ulcers. At each visit the patient also received application of the multivalent silver nanoparticle gel (SilvrSTAT®) to the left ulcer. The weekly visits were followed by instructions to apply the multivalent silver nanoparticle gel to the wound on her left foot and another hydrogel to the wound on her right foot. Using this technique and monitoring the wounds every week, we saw saw reduction in the size of the wounds, with faster closure of the wound on the left foot.

#### RESULTS

The time for closure of the wound on the left foot, receiving application of the the multivalent silver nanoparticle gel was 6 weeks.

The time for close for the wound on right foot, not receiving application of of the multivalent silver nanoparticle gel was 8 weeks.








Figure 2: Week 6 Wound on Left: Closed




Figure 3: Graph of the kill rate of SilvrSTAT® and showing effectiveness with infection control against common organisms infecting wounds.

KILL TIME STUDY WITH 32 PPM CEL						
ORGANISM	EXPOSURE INTERVAL	AVG. CONTROL TITTER (CFU/ml)	% REDUCTION	LOG REDUCTION		
MRSA	1.88	1.9 X 10 <sup>6</sup>	> 99.99	> 4.98		
	24 HR	1.9 X 105	> 99,99	>4.98		
P. Aeraginesa	1 HB	2.1 X 10 <sup>6</sup>	> 99,99905	> 5.02		
	24 HR	2.1 X 10 <sup>6</sup>	> 99,99905	>5.02		
VILE	1.103	1.9 X 10 <sup>6</sup>	> 99.56	> 2.35		
	24 HR	1.9 X 10 <sup>6</sup>	> 99,90	>5.38		

Figure 4: Kill Time of SilvrSTAT® against common org

#### METHODS

 Standard of care treatment with mechanical debridement was performed initially at every encounter to both wounds.

Sterile Saline was then applied to clean the wounds with infection control and appropriate off-loading of the wounds conducted.

 Application of the multivalent silver nanoparticle gel to the wound on the left, application of another hydrogel to the wound on the right.

The patient was instructed to continue daily application of the gels as noted in Step 3.

### CONCLUSION

Silver properties may have enhanced the healing properties of the wound, causing it to heal faster. The wound treated with the multivalent silver nanoparticle gel closed sooner by two weeks perhaps by the antimicrobial properties associated with silver, however more studies need to be conducted before we can prove this hypothesis. With daily applications of the multivalent silver nanoparticle gel to the wound on the patient's left foot, we saw improvement of healing and time to close as compared to the wound on the patient's right foot. Our results show that multivalent silver nanoengineered technology is an effective and economical hydrogel in wound healing.

#### REFERENCES

- Rigo C, Ferroni L, Tocco I, Roman M, Muniorana I, Gardin C, CaimsWRL, Vindigni V, Azzena B, Barbanie C, Zavan B: Active Silver Nanoparticles for Wound Healing. *Int. J. Mol. Sci.* 14: 4817–4840, 2013.
- Lara H, Garza-Trevino E, Ixtepan-Turrent L, Singh D: Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. *Journal of Nanobiotechnology* 2011, 9:30.
- Humberto L, Ayala-Nuñez N, Ixtepan-Turrent L, Rodriguez-Padilla C: Mode of antiviral action of silver nanoparticles against HIV-1. Journel of Nanoblatechnology 2010, 8:1.
- Liu J, Sonshine D, Shervani S, Hurt R: Controlled Release of Biologically Active Silver from Nanosilver Surfaces. ACS Nano , 4(11): 6903–6913, 2010 November 23.
- Nate Seltenrich Nanosilver Weighing the Risks the Benefits. Environmental Health Perspectives 121(7): A220-A225, 2013.
- Modes Of Action: SilverSTAT®: http://www.silvrstat.com/pdf/silvrstat-modes-of-action.pdf. Accessed 12/05/2013.
- SilvrSTAT Antibacterial Wound Dressing Gel United States Package Insert, ABL Medical Data On File.

Poster Presented at Spring SAW-C 2014 A Novel New Nanoparticle Silver Hydrogel\* on Surgical Sites - A Case Series Eric J. Lullove, DPM CWS FACCWS, Boca Raton, FL West Boca Center for Wound Healing

The investigator retained full independence in the conduct of this research.

### ABSTRACT

Over the years there have been many opportunities to address surgical site contamination and post-operative infections in the outpatient setting. Most notably, since the advent of Methielline-resistant infections and an increasing diabetic patient population (this also includes pre-diabetic patients), the risks for surgery have increased in the ability of a patient to properly heal, even with primary intention dosure.

For centuries, human beings have utilized silver-based dressings and silver fisself as a method of buttling contaminant bacteria and viruses. In today's modern age of medicine, the use of nanometric silver products has become mainstream.

A newer, more agile molecular silver hydrogel has shown effective use in the treatment of nosocomial infections and bacteria. This novel new silver hydrogel is a ga ppm nanoparticle which has multivalent and outlytic antimicrobial properties. The molecular silver hydrogel is multivalent, resulting in multiple electrons being physically pulled from the bacteria cell wall, allowing for rayid antimicrobial effect. Additionally, this multivalent silver hydrogel is catalytic, causing a reaction where the molecular silver remains unbound allowing for use at low concentration and reducing potential side effects.

This new nanoparticle silver hydrogel is elinically indicated for pressure ulcers, dialettic foot ulcers, surgical incision sites, autograft and allograft sites, first and second degree burns, venous stasis ulcers, locerations and abrasions, device insertion site wounds and donor sites.

This case study series will demonstrate this new nanoparticle molecular silver hydrogel and its use in preventing surgical site infections and contamination on high-risk diabetic and peripheral atternial disease patients. The use of this nonoparticle molecular silver hydrogel not only showed high effectiveness in preventing infection or contamination, but as a result, also prevented dehiscence of the surgical sites.

#### METHODS

The purpose of this case study series is to show the use of a new ranoparticle silver hydrogel effect on surgical wound sites both postoperative and during the follow-up phases of surgery, which shows that the use of the hydrogel effectively continues to maintain an antimicrobial layer between the sutures and the incision site.

The use of the nanoparticle silver hydrogel is to maintain a moist bealing environment, but also maintain an antimicrobial environment, capable of destroying and killing bacteria that cause nosocomial postoperative infections.

Applications of nanoparticle silver hydrogel immediately postoperative and at each post-surgical visit until suture removal. All patients were cleared post-surgically of any residual contamination or infection by day 14. There was no evidence of any dehiscence or breakdown of the incision after 14 days.

In short, the use of Nanoparticle silver hydrogel can be beneficial in areas of surgical management of high to low-risk surgical patients in the inputient and outpatient settings where the need for more antibiosis is required in patients past-operatively.

52 y/o diabetic male patient underwent elective corrective repoir for hallox vulgus and predialocated and M21 right foot. Patient was given nanoparticle silver hydrogel immediately post-operative and throughout the duration of post-operative suture care every grid day. Patient satures removed at day 18 without any signs of infection, dehiscence or pull-out from the nanoparticle silver hydrogel.

CASE 1





#### CONCLUSIONS/LIMITATIONS

The above case series demonstrates that the use of a nanoparticle silver hydrogel with a multivalent structure can be used both post-surgically as a primary dressing and post-surgically with an open wound with concomitant use of collagen wound dressings without loss of tissue due to cytotoxicity. The ability of the silver hydrogel to not only entalytically destroy bacteria, but maintain a moist wound healing environment is novel in the marketplace and further controlled studies and/or post-market RCT should be developed to further introduce this product's wound healing principles. Although this is a small sample case series, the author believes that there is enough clinical evidence to show the functional ability of this product in not only elective postsurgical, but in high-risk, highly infected individuals where the need for a more versatile silver hydrogel product can be used.

#### Case 2

56 y/o female patient underwent elective 7 plantar digital neuroplasty to her 3rd interspace right foot. Nanoparticle silver n hydrogel was used post-operatively and changed every 3rd day. Sutures removed at day 15 without pull-out, dehiseence or infection.







### CASE 3

72 y/o male diabetic patient underwent nonelective sargical resection of his 4th metatassal bend secondary to scatter osteoryelits. Wound was closed on day 3 post-operatively with use of nanoparticle silver hydrogel. Wound coapted and healed with every grid day dressing charges at day 21.





#### CASE 4

34 y/o formale understant emergency I&D of abavess to her right foot secondary to IV Dilaudid injection abuse. Wound closed post I&D at day 4, with application of nanoparticle silver hydrogel. Dressing changed weekly x 2.5 weeks until couption of tissues. Sutures removed at day 21 without signs of infection, dehiscence or pullout.



#### CASE 5

38 y/o female was seen for emergency as result of brown-recluse spider bite to right medial lower leg. Wound was treated and irrigated, with nanoparticle silver hydrogel applied post-procedure. Nanoparticle silver hydrogel was used in conjunction with ovine forestomach dermal template to obtain wound closure at work 6 post-procedure. There was no evidence of cytotoxicity with the collagen dressing or recurrence of infection.



#### REFERENCES

- Munger Mark A., Rodwanski Przemysław, Hadlock Greg C., Stoddard Greg, Shaoban Akran, Falecener Fonathan, Gwinger David W., Deering-Rice Cassandra E., In Vivo Human Time-Exposure Study of Onlly Dosed Commercial Silver Nanoparticles, Nanomedicine: Nanotechnology, Biology and Medicine (2013).
- doi:10.1016/j.nano.2013.05.010.
- Nelson Laboratories: Time Kill Study. June 2009 pg 1-8.
- Analytical Resource Laboratory: SilveSTAT Time Kill data vs. 5 other commonly used antibacterials.
- Custellano JJ, Shafi SM, Ko F, Denste G, et al. Comparative evaluation of the silvercontaining antimicrobial dressings and drugs. International Wound Journal. June 2007, Vol. 4, Ischnidt RL, Hadlock O, Scoldard O, Grainger DW and Munger MA.
- Strock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger DW and Munger MA. Assessment of ornly doeed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanobaxicology 2013. Online 1-6.

\*SilvrSTAT® Antibacterial Wound Dressing Gel ABL Medical, LLC, American Fork, UT



# KEY PUBLICATIONS TO DATE.

Journal of Wound Care; North American Supplement, Vol. 26; No. 4; April 2017. The Ability of a Colloidal Silver Gel Wound Dressing to Kill Bacteria In-Vitro and In-Vivo (including 2 Different MRSA Strains).

Anti-Aging Therapeutics, Vol. 11; 2009; Silver Sol and the Successful Treatment of Hospital Acquired MRSA in Human Subjects With Ongoing Infection.

Journal of Scientific Healing and Outcomes Volume 1; July 4, 2009. SilverSol improves wound healing: Case Studies in the use of SilverSol in closing wounds (including MRSA), preventing infection, inflammation and activating stem cells.

Antimicrobial Volume 3; No. 11; April 2011. A Unique SilverSol With Broad Spectrum Antimicrobial Properties.

Current Science, Vol. 91; No. 7; 10 Oct. 2006. Bactericidal Activity of Combinations of Silver-Water Dispersion with 19 Antibiotics Against Seven Microbial Strains.

Nanomedicine: Nanotechnology, Biology, and Medicine.(2013) doi: 10.1016/j.nano.2013.06.010. An In-Vivo Human Time-Exposure Investigation of a Commercial Silver Nano-Particle Solution.

Materials Research Innovations Volume 11; No. 1; 2007 Ultra-dilute Ag-aquasols with extraordinary bactericidal properties: role of the system Ag-O-H20.



# Evolution of Silver.

### **Brief Evolution of Silver Particles Before SilverSol Technology**<sup>®</sup>

ANCIENT REMEDY Silver has been used for thousands of years for its antimicrobial properties.



Mid 19<sup>th</sup> CENTURY Silver lons were isolated using electrodes, direct current and water. 1891 Mild Silver Protein was developed in an attempt to stabilize ionic silver particles.

### **1996 American Biotech Labs** develops a safe, highly stable, multi-

valiant nano-silver particle SilverSol Technology<sup>®</sup>.






## Awards won.



American Biotech Labs, LLC, is an eight time recipient of the Best of State award for Medical Innovation by the premier recognition and rewards program for the State of Utah.

The Best of State Awards are awarded annually to companies deemed to have achieved exceptional excellence in an area of endeavor. Of hundreds of biotech and medical products companies who have facilities in the state, the 2007, 2009, 2011, 2015-2018 winner was American Biotech Labs.





10035503 HIT

# **Questions & Answers**

For medical responses or data on file, contact medinfo@ablmedical.com

